Literature DB >> 23685372

A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report.

F Greenway1, S Wang2, M Heiman3.   

Abstract

The gut microbiome plays an important role in regulation of metabolic processes, including digestion, absorption, and synthesis of bioactive molecules that signal physiological host mechanisms. Changes in the human gut microbiome are associated with type 2 diabetes and insulin resistance. Water-soluble dietary fibres like inulin and beta-glucan are fermented in the colon, and beta-glucan increases viscosity. Blueberries improve insulin sensitivity through an antioxidant effect. A cobiotic, consisting of purified inulin, sugar-free blueberry pomace extract, and an oat preparation of purified beta-glucan was developed for twice a day (bid) consumption as a smoothie drink to repair the gastrointestinal dysbiosis in type 2 diabetes. A 30-year-old man presented with new onset type 2 diabetes and a fasting glucose (FBS) of 375 mg/dl. Metformin 500 mg bid was initiated and increased to 1 g bid after 1 week. During the first 9 days of metformin treatment, he developed diarrhoea, but his FBS only dropped to 325 mg/dl. The cobiotic bid was added on the 9th day of metformin treatment, and after 2 days, his FBS dropped to 175 mg/dl. After 8 weeks on metformin and the cobiotic, his blood sugar was 100 mg/dl and he lost 5.5 kg. His stools became soft and formed on the cobiotic, reverted to diarrhoea when off of it for 2 days, and returned to normal on resuming the cobiotic formulation. Metformin is a safe, effective and inexpensive generic medication favouring weight loss, recommended as initial treatment of type 2 diabetes by the American Diabetes Association. However, a 20% incidence of diarrhoea limits its tolerability. A safe food supplement that can increase the efficacy of metformin and its tolerability, as occurred in this case report, would have significant positive public health consequences. A controlled clinical trial of the cobiotic with metformin is planned.

Entities:  

Keywords:  beta-glucan; diarrhoea; inulin

Mesh:

Substances:

Year:  2014        PMID: 23685372     DOI: 10.3920/BM2012.0063

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  13 in total

1.  A novel cobiotic-based preventive approach against high-fat diet-induced adiposity, nonalcoholic fatty liver and gut derangement in mice.

Authors:  D P Singh; P Khare; J Zhu; K K Kondepudi; J Singh; R K Baboota; R K Boparai; R Khardori; K Chopra; M Bishnoi
Journal:  Int J Obes (Lond)       Date:  2015-09-23       Impact factor: 5.095

2.  Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial.

Authors:  Candida J Rebello; Jeffrey Burton; Mark Heiman; Frank L Greenway
Journal:  J Diabetes Complications       Date:  2015-09-03       Impact factor: 2.852

3.  Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels.

Authors:  Jeffrey H Burton; Matthew Johnson; Jolene Johnson; Daniel S Hsia; Frank L Greenway; Mark L Heiman
Journal:  J Diabetes Sci Technol       Date:  2015-03-23

4.  Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes.

Authors:  Inês H Vieira; Luísa M Barros; Carla F Baptista; Dírcea M Rodrigues; Isabel M Paiva
Journal:  Clin Diabetes       Date:  2022-01

Review 5.  Ontogeny of early life immunity.

Authors:  David J Dowling; Ofer Levy
Journal:  Trends Immunol       Date:  2014-05-28       Impact factor: 16.687

6.  Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

Authors:  Antonella Napolitano; Sam Miller; Andrew W Nicholls; David Baker; Stephanie Van Horn; Elizabeth Thomas; Deepak Rajpal; Aaron Spivak; James R Brown; Derek J Nunez
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

7.  Solid Dose Form of Metformin with Ethyl Eicosapentaenoic Acid Does Not Improve Metformin Plasma Availability.

Authors:  Jeffrey H Burton; William D Johnson; Frank L Greenway
Journal:  Pharmacol Pharm       Date:  2016-01-14

8.  Genetically Engineered Escherichia coli Nissle 1917 Synbiotics Reduce Metabolic Effects Induced by Chronic Consumption of Dietary Fructose.

Authors:  Chaudhari Archana Somabhai; Ruma Raghuvanshi; G Nareshkumar
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

9.  The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial.

Authors:  Talia Palacios; Luis Vitetta; Samantha Coulson; Claire D Madigan; Gareth S Denyer; Ian D Caterson
Journal:  Trials       Date:  2017-01-09       Impact factor: 2.279

Review 10.  The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus.

Authors:  You Lv; Xue Zhao; Weiying Guo; Ying Gao; Shuo Yang; Zhuo Li; Guixia Wang
Journal:  J Diabetes Res       Date:  2018-05-07       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.